Proteomic profiling: A novel method for differential diagnosis?

Cancer Biology and Therapy

Volumn 6, Issue 3, 2007, Pages 343-345

  Gläsker, Sven ^a   Lonser, Russell R ^a   Okamoto, Hiroaki ^a   Li, Jie ^a   Jaffee, Howard ^a   Oldfield, Edward H ^a   Zhuang, Zhengping ^a   Vortmeyer, Alexander O ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

Hemangioblastoma; Proteomics; Renal carcinoma; Von Hippel Lindau disease

Indexed keywords

ADULT; ARTICLE; BRAIN TUMOR; CASE REPORT; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; FEMALE; HEMANGIOBLASTOMA; HISTOPATHOLOGY; HUMAN; KIDNEY CARCINOMA; METASTASIS; MICRODISSECTION; PHENOTYPE; PROTEIN EXPRESSION; PROTEOMICS; TWO DIMENSIONAL GEL ELECTROPHORESIS; VON HIPPEL LINDAU DISEASE;

EID: 34548225428     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.6.3.3673     Document Type: Article

References (4)

1. Koch CA, Mauro D, Walther MM, et al. Pheochromocytoma in von Hippel-Lindau disease: Distinct histopathologic phenotype compared to pheochromocytoma in multiple endocrine neoplasia type 2. Endocrine Pathology 2002; 13:17-27.
2. Frank TS, Trojanowski JQ, Roberts SA, Brooks JJ. A detailed immunohistochemical analysis of cerebellar hemangioblastoma: An undifferentiated mesenchymal tumor. Mod Pathol 1989; 2:638-51.
3. Jung SM, Kuo TT. Immunoreactivity of CD10 and inhibin alpha in differentiating hemangioblastoma of central nervous system from metastatic clear cell renal cell carcinoma. Mod Pathol 2005; 18:788-94.
4. Furuta M, Weil RJ, Vortmeyer AO, et al. Protein patterns and proteins that identify subtypes of glioblastoma multiforme. Oncogene. 2004; 23:6806-14.